Cite

HARVARD Citation

    Intlekofer, A. et al. (2013). At the Bench: Preclinical rationale for CTLA‐4 and PD‐1 blockade as cancer immunotherapy. Journal of leukocyte biology. 94 (1), pp. 25-39. [Online]. 
  
Back to record